gemfibrozil has been researched along with Coronary Disease in 156 studies
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to investigate whether the PPARalpha activator gemfibrozil prevents or delays the development of AF in patients with coronary heart disease." | 9.14 | Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. ( Adabag, AS; Al Aloul, B; Bertog, S; Bloomfield, HE; Collins, D; Mithani, S, 2009) |
| "The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) showed that gemfibrozil significantly reduced major coronary events in men with known coronary heart disease (CHD)." | 9.13 | Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). ( Bloomfield, HE; Collins, D; McNamara, JR; Robins, SJ, 2008) |
| "It is not known whether PPAR-alpha agonist gemfibrozil is able to exert rapidly its lipid modulating, potential antiinflammatory and antithrombotic effects in patients with non-ST elevation acute coronary syndrome (NSTEACS), as some other lipid lowering drugs e." | 9.12 | [Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor]. ( Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA, 2006) |
| "This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1." | 9.11 | Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004) |
| "Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level." | 9.09 | Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Fye, CL; Linares, E; Robins, SJ; Rubins, HB; Schaefer, EJ; Schectman, G; Wilt, TJ; Wittes, J, 1999) |
| "In men with coronary heart disease, low HDL cholesterol, and low LDL cholesterol, gemfibrozil reduces stroke incidence." | 9.09 | Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). ( Babikian, V; Bloomfield Rubins, H; Brass, LM; Collins, D; Davenport, J; Papademetriou, V; Robins, SJ; Rutan, G; Wagner, S; Wexler, L, 2001) |
| "The effects of gemfibrozil on several indices of haemostatic activity were explored in male patients with coronary heart disease (CHD)." | 9.07 | Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. ( Barzegar, S; Bauer, KA; Foley, AJ; Hughes, LO; Meade, TW; Miller, GJ; Rosenberg, RD; Wilkes, HC, 1992) |
| "In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5." | 9.06 | Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. ( Elo, O; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Manninen, V, 1987) |
| "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome." | 7.73 | Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. ( Kovanen, PT; Manninen, V; Mänttäri, M; Tenkanen, L; Virkkunen, H, 2006) |
| "To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease." | 7.71 | Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002) |
| "Gemfibrozil reduces the estimated risk for myocardial infarction in patients with primary combined hyperlipidaemia at a level no different from the one of the general population." | 7.69 | Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. ( Athyros, VG; Avramidis, MJ; Kontopoulos, AG; Papageorgiou, AA, 1995) |
| "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids." | 6.41 | Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001) |
| "The changes in serum lipids in men treated with gemfibrozil in the Helsinki Heart Study, a controlled primary prevention trial of coronary heart disease, varied according to baseline lipid levels, type of dyslipidaemia, and treatment compliance." | 6.16 | Lipoproteins and coronary heart disease in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Tenkanen, L, 1990) |
| " The objective of this study was to investigate whether the PPARalpha activator gemfibrozil prevents or delays the development of AF in patients with coronary heart disease." | 5.14 | Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. ( Adabag, AS; Al Aloul, B; Bertog, S; Bloomfield, HE; Collins, D; Mithani, S, 2009) |
| "The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) showed that gemfibrozil significantly reduced major coronary events in men with known coronary heart disease (CHD)." | 5.13 | Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). ( Bloomfield, HE; Collins, D; McNamara, JR; Robins, SJ, 2008) |
| "Changes in conventional lipid risk factors with gemfibrozil treatment only partially explain the reductions in coronary heart disease (CHD) events experienced by men in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)." | 5.12 | Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. ( Bloomfield, HE; Collins, D; Freedman, DS; McNamara, JR; Otvos, JD; Robins, SJ; Schaefer, EJ; Shalaurova, I, 2006) |
| "It is not known whether PPAR-alpha agonist gemfibrozil is able to exert rapidly its lipid modulating, potential antiinflammatory and antithrombotic effects in patients with non-ST elevation acute coronary syndrome (NSTEACS), as some other lipid lowering drugs e." | 5.12 | [Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor]. ( Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA, 2006) |
| "We present the results of the study of lipid-modulating drugs (pravastatin, atorvastatin, simvastatin, and fibrate gemfibrozil) in complicated coronary heart disease (acute coronary syndrome without ST elevation, chronic heart failure." | 5.12 | Use of lipid-modulating drugs in complicated course of coronary heart disease. ( Gratsianskii, NA; Vaulin, NA, 2007) |
| "This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1." | 5.11 | Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004) |
| "Relation of lipid levels at baseline and averaged during the first 18 months of gemfibrozil treatment with the combined incidence of nonfatal myocardial infarction and CHD death." | 5.09 | Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. ( Collins, D; Deedwania, PC; Hershman, JM; Kashyap, ML; McNamara, JR; Papademetriou, V; Robins, SJ; Rubins, HB; Schaefer, EJ; Wexler, LF; Wittes, JT, 2001) |
| "In men with coronary heart disease, low HDL cholesterol, and low LDL cholesterol, gemfibrozil reduces stroke incidence." | 5.09 | Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). ( Babikian, V; Bloomfield Rubins, H; Brass, LM; Collins, D; Davenport, J; Papademetriou, V; Robins, SJ; Rutan, G; Wagner, S; Wexler, L, 2001) |
| "Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level." | 5.09 | Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Fye, CL; Linares, E; Robins, SJ; Rubins, HB; Schaefer, EJ; Schectman, G; Wilt, TJ; Wittes, J, 1999) |
| " In this study, the area under the curve, maximum plasma concentration, and time to maximum concentration for fluvastatin and gemfibrozil are compared, when used alone and in combination, in patients with hyperlipidemia and either coronary or carotid atherosclerosis, or a family history of coronary artery disease." | 5.08 | Pharmacokinetics of the combination of fluvastatin and gemfibrozil. ( Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD, 1995) |
| " Six hundred and twelve patients with postdiet LDL cholesterol (LDL-C) levels in the range of 190-230 mg/dl (or 160-230 mg/dl for those with coronary heart disease or two or more coronary risk factors) were randomized to a stepped-care regimen (initial treatment with niacin followed by other agents if needed) or to initial use of lovastatin, an HMG-CoA reductase inhibitor." | 5.08 | A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). ( Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V, 1995) |
| "To confirm that coronary heart disease (CHD) can be prevented by gemfibrozil treatment and to estimate the long-term effect of the treatment." | 5.07 | The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Tenkanen, L, 1994) |
| "During screening in the Helsinki Heart Study (HHS), a 5-year coronary primary prevention trial with gemfibrozil, some 600 dyslipidaemic individuals were detected who exhibited symptoms and signs of possible coronary heart disease (CHD)." | 5.07 | Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M, 1993) |
| "The effects of gemfibrozil on several indices of haemostatic activity were explored in male patients with coronary heart disease (CHD)." | 5.07 | Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. ( Barzegar, S; Bauer, KA; Foley, AJ; Hughes, LO; Meade, TW; Miller, GJ; Rosenberg, RD; Wilkes, HC, 1992) |
| " This was a controlled primary prevention trial to test the hypothesis that using gemfibrozil to lower the concentrations of serum low density lipoprotein (LDL) and very low density lipoprotein (VLDL) and to raise that of high density lipoprotein (HDL) protects subjects against coronary heart disease." | 5.07 | The Helsinki Heart Study: central findings and clinical implications. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Romo, M; Tenkanen, L, 1991) |
| "All participants of the Helsinki Heart Study (a controlled, 5-year, multi-clinic coronary heart disease (CHD) primary prevention trial with gemfibrozil and placebo) were offered gemfibrozil treatment and twice yearly follow-up for 3." | 5.07 | The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. ( Frick, MH; Hakulinen, T; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Teppo, L, 1994) |
| "A 34% reduction in the incidence of definite coronary heart disease events was observed in dyslipidemic men treated with gemfibrozil in the Helsinki Heart Study, a controlled 5-year, double-blind primary prevention trial for coronary heart disease." | 5.06 | Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Manninen, V; Tenkanen, L, 1989) |
| " The study has the following 3 key objectives: to define the cost effectiveness of gemfibrozil in the prevention of coronary heart disease (CHD); to assess the net impact of gemfibrozil on total treatment costs for CHD; and to identify those patient groups for whom gemfibrozil therapy is most cost effective." | 5.06 | Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. ( Fifer, SK; Sarma, S, 1990) |
| "In the Helsinki Heart Study, a randomized five-year, double-blind trial, a 34% reduction in the incidence of coronary heart disease (CHD) was observed in dyslipidemic men treated with gemfibrozil." | 5.06 | Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. ( Elo, MO; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Manninen, V, 1988) |
| "In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5." | 5.06 | Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. ( Elo, O; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Manninen, V, 1987) |
| " Its aim is to investigate the effects on the incidence of coronary heart disease of simultaneously lowering serum total and low density lipoprotein (LDL)-cholesterol and elevating high density lipoprotein (HDL)-cholesterol with gemfibrozil, over a period of 5 years." | 5.06 | The Helsinki Heart Study: basic design and randomization procedure. ( Elo, O; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Mänttäri, M, 1987) |
| " Efficacy of gemfibrozil was demonstrated in secondary stroke prevention in patients with coronary heart disease and elevated triglyceride levels." | 4.89 | Hypertriglyceridemia as a possible independent risk factor for stroke. ( Basić-Kes, V; Demarin, V; Lisak, M; Trkanjec, Z, 2013) |
| "Two major trials, the Bezafibrate Infarction Prevention Trial (BIP) and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) were conducted to clarify the contribution of correcting diminished high density lipoprotein (HDL) (and lowering triglyceride, TG) levels to the risk of cardiovascular events in patients with coronary heart disease (CHD)." | 4.81 | Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. ( Mikhailidis, DP; Rizos, E, 2002) |
| "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome." | 3.73 | Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. ( Kovanen, PT; Manninen, V; Mänttäri, M; Tenkanen, L; Virkkunen, H, 2006) |
| "To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease." | 3.71 | Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002) |
| "Gemfibrozil reduces the estimated risk for myocardial infarction in patients with primary combined hyperlipidaemia at a level no different from the one of the general population." | 3.69 | Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. ( Athyros, VG; Avramidis, MJ; Kontopoulos, AG; Papageorgiou, AA, 1995) |
| "3 mmol/l profited most from treatment with gemfibrozil, with a 71% lower incidence of coronary heart disease events than the corresponding placebo subgroup." | 3.68 | Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Tenkanen, L, 1992) |
| "Gemfibrozil treatment was associated with 3% to 6% decreases in the small, lipid-poor prebeta-1 HDL and in the large, lipid-rich alpha-1 and alpha-2 HDL and with increases in the small alpha-3 (3%) and prealpha-3 (16%) HDLs." | 2.73 | Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. ( Asztalos, BF; Bloomfield, HE; Collins, D; Horvath, KV; Robins, SJ; Schaefer, EJ, 2008) |
| "Gemfibrozil treatment lowered plasma triglycerides and both total and very low-density lipoprotein (VLDL)-cholesterol (P < 0." | 2.69 | Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. ( Aberg, F; Angelin, B; Appelkvist, EL; Bröijersén, A; Dallner, G; Eriksson, M; Hjemdahl, P, 1998) |
| "The progression of coronary atherosclerosis was estimated by quantitative, computer-assisted analysis of coronary artery stenoses from the baseline angiograms and from repeated angiograms performed an average of 32 months later." | 2.69 | Heart rate variability and progression of coronary atherosclerosis. ( Airaksinen, KE; Frick, MH; Huikuri, HV; Ikäheimo, MJ; Jokinen, V; Kauma, H; Kesäniemi, AY; Koistinen, JM; Majahalme, S; Niemelä, KO; Nieminen, MS; Syvänne, M, 1999) |
| "Compared with nondiabetic subjects, NIDDM patients had lower HDL cholesterol (P less than 0." | 2.67 | Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M, 1992) |
| " Reduced dosage was easily detected in the marker results." | 2.66 | Minimal doses of digoxin: a new marker for compliance to medication. ( Heinonen, OP; Javela, K; Mäenpää, H; Mälkönen, M; Manninen, V; Pikkarainen, J, 1987) |
| " In the poor compliance group, defined with the use of the digoxin marker, there was 39% of subjects who returned less than 5% of their capsule dosage or reported a deviation less than 5%." | 2.66 | Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. ( Heinonen, OP; Mäenpää, H; Manninen, V, 1987) |
| " Although the National Cholesterol Education Programme Adult Treatment Panel III guidelines recommend the use of fibrates in combination with statins in patients at very high risk of CHD (e." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "Exaggerated postprandial hyperlipidemia has been associated with cardiovascular disease." | 2.41 | Postprandial lipemia--effect of lipid-lowering drugs. ( Karpe, F, 2002) |
| "The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), in which subjects were randomized to treatment with lovastatin or placebo, also reported a striking benefit of treatment, particularly in patients with HDL-C < or =35 mg/dL at baseline." | 2.41 | High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. ( Boden, WE, 2000) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids." | 2.41 | Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001) |
| " A metaanalysis of ten trials has shown a 25% decrease in vascular events in the long-term, irrespective of age, gender, blood pressure blood glucose level, and dosage whether low (75 to 160 mg) or moderate (160 to 325 mg/day)." | 2.39 | [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents]. ( Aumont, MC; Seknadji, P, 1996) |
| "Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance." | 2.39 | Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994) |
| "Hyperlipidemia is a well-recognized complication of renal transplantation." | 2.38 | Hyperlipidemia and transplantation: etiologic factors and therapy. ( Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW, 1992) |
| "Simvastatin was associated with a reduced risk of MACE (HR 0." | 1.72 | Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients. ( Blais, JE; Chan, EW; Tomlinson, B; Wan, EYF; Wong, ICK; Wong, WCW; Ye, X, 2022) |
| "Over the last three decades, hypolipemiants like fibric acid derivatives and statins have been increasingly recognised as causes of rhabdomyolysis and acute renal failure especially during combination therapy and in the presence of underlying renal impairment." | 1.31 | Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. ( Kamaliah, MD; Sanjay, LD, 2001) |
| "Tuboeruptive xanthomata, palmar xanthoma, and xanthoma striata palmare subsided with treatment." | 1.27 | Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease. ( Dodge, HT; Kostis, JB; Kuo, PT; Moreyra, AB; Wilson, AC, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (16.03) | 18.7374 |
| 1990's | 62 (39.74) | 18.2507 |
| 2000's | 64 (41.03) | 29.6817 |
| 2010's | 4 (2.56) | 24.3611 |
| 2020's | 1 (0.64) | 2.80 |
| Authors | Studies |
|---|---|
| Blais, JE | 1 |
| Ye, X | 1 |
| Wan, EYF | 1 |
| Wong, WCW | 1 |
| Wong, ICK | 1 |
| Tomlinson, B | 1 |
| Chan, EW | 1 |
| Lisak, M | 1 |
| Demarin, V | 1 |
| Trkanjec, Z | 1 |
| Basić-Kes, V | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| McBride, P | 1 |
| Adabag, AS | 1 |
| Mithani, S | 1 |
| Al Aloul, B | 1 |
| Collins, D | 12 |
| Bertog, S | 1 |
| Bloomfield, HE | 5 |
| Gupta, A | 1 |
| Guyomard, V | 1 |
| Zaman, MJ | 1 |
| Rehman, HU | 1 |
| Myint, PK | 1 |
| Peloso, GM | 1 |
| Demissie, S | 2 |
| Mirel, DB | 1 |
| Gabriel, SB | 1 |
| Cupples, LA | 2 |
| Robins, SJ | 13 |
| Schaefer, EJ | 8 |
| Brousseau, ME | 3 |
| O'Connor, JJ | 1 |
| Ordovas, JM | 2 |
| Otvos, JD | 2 |
| Massov, T | 1 |
| McNamara, JR | 4 |
| Rubins, HB | 7 |
| Kolovou, GD | 1 |
| Cokkinos, DV | 1 |
| Fruchart, JC | 3 |
| Duriez, P | 1 |
| Packard, KA | 1 |
| Backes, JM | 2 |
| Lenz, TL | 1 |
| Wurdeman, RL | 1 |
| Destache, C | 1 |
| Hilleman, DE | 1 |
| Vajo, Z | 1 |
| Reaven, PD | 1 |
| Zhao, SP | 1 |
| Ye, HJ | 1 |
| Zhou, HN | 1 |
| Nie, S | 1 |
| Li, QZ | 1 |
| Boden, WE | 4 |
| Viles-Gonzalez, JF | 1 |
| Fuster, V | 1 |
| Corti, R | 1 |
| Badimon, JJ | 1 |
| Poppius, E | 1 |
| Tenkanen, L | 11 |
| Hakama, M | 1 |
| Kalimo, R | 1 |
| Pitkänen, T | 1 |
| Kervinen, H | 1 |
| Huittinen, T | 1 |
| Vaarala, O | 1 |
| Leinonen, M | 1 |
| Saikku, P | 1 |
| Manninen, V | 23 |
| Mänttäri, M | 17 |
| Talmud, PJ | 2 |
| Martin, S | 1 |
| Taskinen, MR | 5 |
| Frick, MH | 20 |
| Nieminen, MS | 4 |
| Kesäniemi, YA | 3 |
| Pasternack, A | 3 |
| Humphries, SE | 2 |
| Syvänne, M | 6 |
| Goldkamp, AL | 1 |
| Connolly, AC | 1 |
| Tonelli, M | 1 |
| Robins, S | 1 |
| Bloomfield, H | 1 |
| Curhan, GC | 1 |
| Whitney, EJ | 2 |
| Krasuski, RA | 1 |
| Personius, BE | 2 |
| Michalek, JE | 1 |
| Maranian, AM | 1 |
| Kolasa, MW | 1 |
| Monick, E | 1 |
| Brown, BG | 1 |
| Gotto, AM | 2 |
| Hay, JW | 1 |
| Sterling, KL | 1 |
| Davidson, MH | 1 |
| Freedman, DS | 1 |
| Shalaurova, I | 1 |
| Barter, PJ | 2 |
| Rye, KA | 1 |
| Kovanen, PT | 1 |
| Virkkunen, H | 2 |
| Vaulin, NA | 2 |
| Pokrovskaia, EV | 1 |
| Deev, AD | 1 |
| Gratsianskiĭ, NA | 2 |
| Gibson, CA | 1 |
| Ruisinger, JF | 1 |
| Moriarty, PM | 1 |
| Asztalos, BF | 1 |
| Horvath, KV | 1 |
| Härmä, M | 1 |
| Kauppinen, T | 1 |
| Nash, DT | 2 |
| Tiula, E | 1 |
| Alikoski, T | 2 |
| Spence, JD | 1 |
| Munoz, CE | 1 |
| Hendricks, L | 1 |
| Latchinian, L | 1 |
| Khouri, HE | 1 |
| Gould, AL | 1 |
| Rossouw, JE | 1 |
| Santanello, NC | 1 |
| Heyse, JF | 1 |
| Furberg, CD | 1 |
| Schonfeld, G | 1 |
| Oster, G | 1 |
| Borok, GM | 1 |
| Menzin, J | 1 |
| Heys, JF | 1 |
| Epstein, RS | 1 |
| Quinn, V | 1 |
| Benson, VV | 1 |
| Dudl, RJ | 1 |
| Epstein, A | 1 |
| Athyros, VG | 2 |
| Papageorgiou, AA | 2 |
| Avramidis, MJ | 1 |
| Kontopoulos, AG | 2 |
| Lozada, A | 1 |
| Dujovne, CA | 1 |
| Yuan, J | 1 |
| Tsai, MY | 1 |
| Hunninghake, DB | 2 |
| Winocour, PH | 1 |
| Kuo, PT | 2 |
| Welborn, TA | 1 |
| Hautanen, A | 1 |
| Huttunen, JK | 15 |
| Adlercreutz, H | 1 |
| Kingswell, RS | 1 |
| Kahri, J | 1 |
| Vuorinen-Markkola, H | 1 |
| Tilly-Kiesi, M | 1 |
| Lahdenperä, S | 1 |
| Olsson, AG | 2 |
| Heinonen, OP | 14 |
| Koskinen, P | 12 |
| Hakulinen, T | 1 |
| Teppo, L | 1 |
| Javela, K | 2 |
| Pikkarainen, J | 2 |
| Newman, TB | 1 |
| Iwane, MK | 2 |
| Elam, MB | 2 |
| Fye, CL | 2 |
| Gordon, DJ | 1 |
| Schectman, G | 3 |
| Wittes, JT | 2 |
| Kreisberg, RA | 1 |
| Peace, KE | 1 |
| Carter, WH | 1 |
| Santos, RD | 1 |
| Mansur, AP | 1 |
| Safi Júnior, J | 1 |
| Giraldez, RR | 1 |
| Maranhão, RC | 1 |
| Pileggi, F | 1 |
| Ramires, JA | 1 |
| Hiatt, J | 1 |
| Gibaldi, M | 1 |
| Kradjan, W | 1 |
| Tikkanen, MJ | 1 |
| Aumont, MC | 1 |
| Seknadji, P | 1 |
| Schiel, R | 1 |
| Bambauer, R | 1 |
| Müller, UA | 1 |
| Nawrocki, JW | 1 |
| Haber, H | 1 |
| Haffner, SM | 1 |
| Perreault, S | 1 |
| Hamilton, VH | 1 |
| Lavoie, F | 1 |
| Grover, S | 1 |
| Havel, RJ | 1 |
| Andrews, TC | 1 |
| Green, G | 1 |
| Kalenian, R | 1 |
| Brewer, HB | 1 |
| Leitersdorf, E | 1 |
| Aberg, F | 1 |
| Appelkvist, EL | 1 |
| Bröijersén, A | 1 |
| Eriksson, M | 1 |
| Angelin, B | 1 |
| Hjemdahl, P | 1 |
| Dallner, G | 1 |
| Staels, B | 1 |
| Koenig, W | 1 |
| Habib, A | 1 |
| Merval, R | 1 |
| Lebret, M | 1 |
| Torra, IP | 1 |
| Delerive, P | 1 |
| Fadel, A | 1 |
| Chinetti, G | 1 |
| Najib, J | 1 |
| Maclouf, J | 1 |
| Tedgui, A | 1 |
| Luong, LA | 2 |
| Wittes, J | 2 |
| Collins, DE | 1 |
| Anderson, JW | 1 |
| Faas, FH | 1 |
| Linares, E | 1 |
| Wilt, TJ | 1 |
| Huikuri, HV | 1 |
| Jokinen, V | 1 |
| Airaksinen, KE | 1 |
| Ikäheimo, MJ | 1 |
| Koistinen, JM | 1 |
| Kauma, H | 1 |
| Kesäniemi, AY | 1 |
| Majahalme, S | 1 |
| Niemelä, KO | 1 |
| Alpert, JS | 1 |
| Scheen, AJ | 1 |
| Hamsten, A | 1 |
| Silveira, A | 1 |
| Humphries, S | 1 |
| Cramb, R | 1 |
| Guyton, JR | 1 |
| Blazing, MA | 1 |
| Hagar, J | 1 |
| Kashyap, ML | 2 |
| Knopp, RH | 1 |
| McKenney, JM | 1 |
| Nash, SD | 1 |
| Schmitz, G | 1 |
| Lackner, KJ | 1 |
| Gaziano, JM | 1 |
| Jones, PH | 2 |
| Nass, CM | 1 |
| Wiviott, SD | 1 |
| Allen, JK | 1 |
| Post, WS | 1 |
| Blumenthal, aR | 1 |
| Krakoff, J | 1 |
| Vela, BS | 1 |
| Brinton, EA | 1 |
| Durrington, P | 1 |
| Pearson, TA | 1 |
| Ogunko, A | 1 |
| Oboubie, K | 1 |
| Plutzky, J | 1 |
| Ridker, PM | 1 |
| Oldemeyer, JB | 1 |
| Lund, RJ | 1 |
| Koch, M | 1 |
| Meares, AJ | 1 |
| Dunlay, R | 1 |
| Watts, GF | 1 |
| Dimmitt, SB | 1 |
| Papademetriou, V | 2 |
| Deedwania, PC | 1 |
| Hershman, JM | 1 |
| Wexler, LF | 1 |
| Sekiya, M | 1 |
| Ishibashi, S | 1 |
| Noto, H | 1 |
| Kinoshita, M | 1 |
| Tada, N | 1 |
| Miller, M | 1 |
| Sprecher, DL | 1 |
| Bloomfield Rubins, H | 1 |
| Davenport, J | 1 |
| Babikian, V | 1 |
| Brass, LM | 1 |
| Wexler, L | 1 |
| Wagner, S | 1 |
| Rutan, G | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Breuer, HW | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Doggrell, SA | 1 |
| Rizos, E | 2 |
| Mikhailidis, DP | 3 |
| Kamaliah, MD | 1 |
| Sanjay, LD | 1 |
| Platts, J | 1 |
| Wierzbicki, AS | 1 |
| Karpe, F | 1 |
| Pirsch, JD | 1 |
| D'Alessandro, AM | 1 |
| Sollinger, HW | 1 |
| Knechtle, SJ | 1 |
| Reed, A | 1 |
| Kalayoglu, M | 1 |
| Belzer, FO | 1 |
| Wilkes, HC | 1 |
| Meade, TW | 1 |
| Barzegar, S | 1 |
| Foley, AJ | 1 |
| Hughes, LO | 1 |
| Bauer, KA | 1 |
| Rosenberg, RD | 1 |
| Miller, GJ | 1 |
| Bobbio, M | 1 |
| Brusca, A | 1 |
| Romo, M | 2 |
| Sarma, S | 1 |
| Fifer, SK | 1 |
| Miller, NE | 1 |
| Ahuja, IM | 1 |
| Canter, D | 1 |
| Frick, HM | 1 |
| Janus, ED | 1 |
| Islami, Y | 1 |
| Ribeiro, LG | 1 |
| Heinsalmi, P | 4 |
| Grundy, SM | 2 |
| Elo, MO | 1 |
| Haapa, K | 3 |
| Helo, P | 3 |
| Kaitaniemi, P | 3 |
| Wilson, AC | 1 |
| Kostis, JB | 1 |
| Moreyra, AB | 1 |
| Dodge, HT | 1 |
| Bell, H | 1 |
| Dittmeier, G | 1 |
| Martinez, L | 1 |
| Elo, O | 2 |
| Rifkind, BM | 1 |
| Naito, HK | 1 |
| Mäenpää, H | 2 |
| Mälkönen, M | 1 |
| Scott, LW | 1 |
| Vega, GL | 1 |
| Oliver, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol[NCT00283335] | Phase 3 | 2,531 participants (Actual) | Interventional | 1991-06-30 | Completed | ||
| Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485] | Phase 3 | 9 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Unable to recruit sufficient study subjects) | ||
| Effects of Low Carbohydrate Diet Compared to Low Fat Diet in Reversing the Metabolic Syndrome Using NCEP ATP III Criteria; Randomized Clinical Trial[NCT04681924] | 94 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| Treatment Study for Severe High-Density Lipoprotein Deficiency[NCT00458055] | 19 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation[NCT00166712] | Phase 4 | 40 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Study stopped due to lack of efficacy & funding.) | ||
| Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes (T2DM)[NCT00577590] | 78 participants (Actual) | Interventional | 2003-10-31 | Completed | |||
| Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy[NCT00469911] | 18 participants (Actual) | Interventional | 2005-08-31 | Completed | |||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00108485)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Number) |
|---|---|
| Extended Release Niacin | 42 |
| Placebo | 63 |
The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant. (NCT00166712)
Timeframe: Within 12 months post kidney transplant
| Intervention | Participants (Number) |
|---|---|
| Groups | 4 |
| Group 2 | 6 |
(NCT00577590)
Timeframe: Baseline and 3 months
| Intervention | percent change (Mean) | |
|---|---|---|
| Plasma triglycerides women | Plasma triglycerides men | |
| Metformin | 16.0 | -10.0 |
| Metformin and Lovaza | -2.0 | -5.0 |
| Metformin and Rosiglitazone | -5.0 | 1.0 |
Participants first had MRS spectroscopy then the MRS spectroscopy images were compared to endomyocardial biopsy (NCT00469911)
Timeframe: 2 to 10 days
| Intervention | correlation co-efficient (Number) |
|---|---|
| Heart Transplant Patients | 0.97 |
52 reviews available for gemfibrozil and Coronary Disease
| Article | Year |
|---|---|
Hypertriglyceridemia as a possible independent risk factor for stroke.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hypertriglyceridemia; Hyp | 2013 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Triglycerides and risk for coronary artery disease.
Topics: Alcohol Drinking; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Hydroxym | 2008 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combinat | 2010 |
Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment.
Topics: Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Risk | 2002 |
HDL and triglyceride as therapeutic targets.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, T | 2002 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Thera | 2003 |
Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.
Topics: Animals; Cholesterol, HDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Endotheli | 2003 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil | 2004 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
Topics: Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; | 2006 |
Fibrates: what have we learned in the past 40 years?
Topics: Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutar | 2007 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Cholesterol reduction yields clinical benefit. A new look at old data.
Topics: Cholesterol; Cholesterol, Dietary; Clofibrate; Coronary Disease; Dextrothyroxine; Estrogens; Gemfibr | 1995 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru | 1994 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H | 1994 |
Dyslipidaemia in non-insulin dependent diabetes: the need for a clinical intervention trial.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diabetes Mellitus, Type 2; | 1994 |
Treating elevated cholesterol levels: the great Satan in perspective.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; | 1996 |
Selection of appropriate type and intensity of lipid-lowering therapy.
Topics: Cholesterol; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Enzyme Inhibit | 1995 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyp | 1996 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
Topics: Animals; Cholesterol, LDL; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hydroxymethylg | 1998 |
[Lipid-related prevention of coronary disease without reduction of LDL-cholesterol. Two new intervention studies show that the old truths must be modified].
Topics: Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Fatty Acids, Omega-3; Gemfi | 2000 |
[Low HDL-cholesterol].
Topics: Cholesterol, HDL; Coronary Disease; Gemfibrozil; Genetic Predisposition to Disease; Humans; Hypolipi | 2000 |
Triglycerides and coronary risk.
Topics: Biomarkers; Coronary Disease; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agent | 1999 |
Fibrates and high-dose statins to prevent coronary heart disease events.
Topics: Angioplasty, Balloon, Coronary; Bezafibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipi | 1999 |
The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Gemfibro | 2000 |
Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; | 2000 |
Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypol | 2001 |
[Helsinki Heart Study].
Topics: Adult; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids | 2001 |
[VA-HIT Study [Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study]].
Topics: Aged; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Hypolipoprotein | 2001 |
[Gemfibrozil: new aspects in clinical use].
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperli | 2001 |
High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Female; Gemfibr | 2000 |
Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Confounding Factors, Epidemiologic; Coronary Disea | 2000 |
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil | 2000 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyd | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combin | 2001 |
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
Topics: Adult; Bezafibrate; Biomarkers; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Gemfibrozi | 2001 |
Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial.
Topics: Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Hypolipoproteinemias; | 2001 |
Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.
Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; | 2002 |
Beyond LDL-C--the importance of raising HDL-C.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hydroxy | 2002 |
Postprandial lipemia--effect of lipid-lowering drugs.
Topics: Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2002 |
Hyperlipidemia and transplantation: etiologic factors and therapy.
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans; | 1992 |
Lipoproteins and coronary heart disease in the Helsinki Heart Study.
Topics: Coronary Disease; Gemfibrozil; Humans; Incidence; Lipids; Lipoproteins | 1990 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
Pharmacological intervention for altering lipid metabolism.
Topics: Animals; Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Lipid Metabolism; Lipids; Niac | 1990 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi | 1987 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
62 trials available for gemfibrozil and Coronary Disease
| Article | Year |
|---|---|
Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.
Topics: Aged; Atrial Fibrillation; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method | 2009 |
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
Topics: Alleles; Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; C | 2002 |
Managing lipid disorders: further evaluation of the VA-HIT.
Topics: Adult; Aged; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Humans; Hypolip | 2003 |
The sense of coherence, occupation and all-cause mortality in the Helsinki Heart Study.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Coronary Disease; Finland; Gemfibrozil; Holistic | 2003 |
Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial.
Topics: Aged; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Gene Frequency; Humans; Lipoprotein Lipase; L | 2004 |
Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Topics: Aged; Cholesterol, HDL; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; F | 2004 |
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progre | 2005 |
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Topics: Aged; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Lipoproteins, H | 2006 |
[Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor].
Topics: Acute Disease; Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Coronary Disease; Electrocardiogra | 2006 |
Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).
Topics: Aged; Body Weight; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; In | 2008 |
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Topics: Cardiovascular Diseases; Coronary Disease; Gemfibrozil; Humans; Hypertension; Hypolipidemic Agents; | 2008 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfib | 2007 |
Effects of hypertension and dyslipidemia on the decline in renal function.
Topics: Adult; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Creatin | 1995 |
Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Stenosis; Coronary Artery Disease; Coronary Dise | 1995 |
Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Gemf | 1995 |
Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study.
Topics: Cholesterol, HDL; Confidence Intervals; Coronary Angiography; Coronary Artery Bypass; Coronary Disea | 1994 |
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Fol | 1995 |
Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.
Topics: Adult; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperch | 1994 |
Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study.
Topics: Adrenal Glands; Age Factors; Androgens; Androstane-3,17-diol; Androstenedione; Blood Pressure; Case- | 1994 |
Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity.
Topics: Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Coronary | 1993 |
The Helsinki Heart Study: an 8.5-year safety and mortality follow-up.
Topics: Adult; Cause of Death; Coronary Disease; Finland; Follow-Up Studies; Gemfibrozil; Humans; Incidence; | 1994 |
The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up.
Topics: Adult; Coronary Disease; Finland; Follow-Up Studies; Gemfibrozil; Humans; Incidence; Male; Middle Ag | 1994 |
Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lip
Topics: Adult; Aged; Cause of Death; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols; Coronary Diseas | 1993 |
Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Gemfi | 1993 |
Exposure analysis of dichotomous response measures in long-term studies.
Topics: Analysis of Variance; Coronary Disease; Data Interpretation, Statistical; Double-Blind Method; Gemfi | 1993 |
[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].
Topics: Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cor | 1995 |
The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-D
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemi | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, | 1995 |
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. L
Topics: Cholesterol, HDL; Cineangiography; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; D | 1997 |
Alcohol and coronary heart disease: the roles of HDL-cholesterol and smoking.
Topics: Adult; Alcohol Drinking; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Gemfibrozil; Human | 1997 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Co | 1997 |
Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia.
Topics: Adult; Aged; Antioxidants; Apolipoproteins; Case-Control Studies; Coronary Disease; Cross-Over Studi | 1998 |
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.
Topics: Aged; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Gemfibrozil; | 1998 |
Simultaneous screening for three correlated lipids in the VA HDL Intervention Trial.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Computer Simulation; Coronary Disease; Double-Blind Method | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Heart rate variability and progression of coronary atherosclerosis.
Topics: Analysis of Variance; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Disease Progr | 1999 |
[Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
Topics: Adult; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Female; Gemfibrozil; Humans; Hypolip | 1999 |
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Topics: Aged; Coronary Disease; Fibrinolysis; Gemfibrozil; Genotype; Humans; Hypolipidemic Agents; Male; Mid | 2000 |
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub | 2000 |
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Gemfibrozil; Humans; Hypo | 2001 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; | 2001 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease.
Topics: Biomarkers; Blood Coagulation; Coronary Disease; Double-Blind Method; Gemfibrozil; Humans; Male; Pat | 1992 |
The Helsinki Heart Study: central findings and clinical implications.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Double-Blind Method; | 1991 |
Lipoproteins and coronary heart disease in the Helsinki Heart Study.
Topics: Coronary Disease; Gemfibrozil; Humans; Incidence; Lipids; Lipoproteins | 1990 |
Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy.
Topics: Adult; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle A | 1990 |
Management of hyperlipidaemia: the Helsinki Heart Study.
Topics: Coronary Disease; Finland; Gemfibrozil; Humans; Hypercholesterolemia | 1989 |
Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
Topics: Adult; Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1989 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up | 1988 |
Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1988 |
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
Topics: Adult; Coronary Disease; Double-Blind Method; Finland; Gemfibrozil; Humans; Hypolipidemic Agents; Li | 1988 |
Gemfibrozil therapy in patients with coronary heart disease.
Topics: Adult; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Female; Gemfibrozil; Humans; Hy | 1988 |
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; | 1987 |
Gemfibrozil, lipids, and coronary risk.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; | 1987 |
The Helsinki Heart Study: basic design and randomization procedure.
Topics: Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease | 1987 |
Minimal doses of digoxin: a new marker for compliance to medication.
Topics: Clinical Trials as Topic; Coronary Disease; Creatinine; Digoxin; Double-Blind Method; Finland; Follo | 1987 |
Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial.
Topics: Capsules; Clinical Trials as Topic; Coronary Disease; Creatinine; Digoxin; Double-Blind Method; Finl | 1987 |
Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipide | 1985 |
Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1985 |
The Gemfibrozil Study.
Topics: Adult; Clinical Trials as Topic; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipidemic Agents | 1985 |
45 other studies available for gemfibrozil and Coronary Disease
| Article | Year |
|---|---|
Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients.
Topics: Cohort Studies; Coronary Disease; Female; Gemfibrozil; Humans; Male; Primary Health Care; Primary Pr | 2022 |
Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.
Topics: Aged; Alleles; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Genetic Predis | 2010 |
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
Topics: Aged; Chi-Square Distribution; Coronary Disease; Cross-Over Studies; Female; Fenofibrate; Gemfibrozi | 2002 |
Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease.
Topics: Aged; Angiotensin II; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; Cells, Cultured; Coronary | 2003 |
Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk.
Topics: Antibodies; Chaperonin 60; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hyp | 2003 |
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.
Topics: Aged; Apolipoprotein A-V; Apolipoproteins; Apolipoproteins A; Arteriosclerosis; Coronary Disease; Di | 2004 |
Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progre | 2005 |
Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Topics: Aged; Cholesterol, HDL; Coronary Disease; Cost-Benefit Analysis; Female; Fenofibrate; Gemfibrozil; H | 2005 |
Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.
Topics: Coronary Disease; Double-Blind Method; Dyslipidemias; Follow-Up Studies; Gemfibrozil; Humans; Hypoli | 2006 |
Shift work, occupational noise and physical workload with ensuing development of blood pressure and their joint effect on the risk of coronary heart disease.
Topics: Adult; Blood Pressure; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hypertension; Hypol | 2007 |
Hyperlipidemia: reducing the chances of cardiovascular disease.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemia | 1984 |
Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
Topics: Coronary Disease; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lipids; Male; Midd | 1995 |
Nutrition and therapeutics.
Topics: Cholesterol; Coronary Disease; Gemfibrozil; Humans | 1994 |
Consensus conferences as drug promotion.
Topics: Advertising; Consensus Development Conferences as Topic; Coronary Disease; Drug Industry; Gemfibrozi | 1993 |
Two follow-up studies of preventive lipid-lowering trials support the validity of the lipid hypothesis.
Topics: Clinical Trials as Topic; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; | 1994 |
Seasonal variation in high density lipoprotein cholesterol.
Topics: Adult; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; | 1993 |
Possibly disappointing results of treatment with gemfibrozil.
Topics: Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans | 1993 |
Low high-density lipoprotein cholesterol: what does it mean, what can we do about it, and what should we do about it?
Topics: Adult; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Male; Middle Aged; Risk Factors | 1993 |
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil; | 1996 |
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Hu | 1997 |
Benefits of fibrate drugs in coronary heart disease patients with normal cholesterol levels.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Diseas | 1997 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox | 1998 |
Choice of lipid-lowering drugs.
Topics: Animals; Cholestyramine Resin; Coronary Disease; Estrogen Replacement Therapy; Gemfibrozil; Humans; | 1998 |
HDL on the rise.
Topics: Cholesterol, HDL; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Triglyc | 1999 |
Therapy and clinical trials.
Topics: Coronary Disease; Endothelium, Vascular; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Gemfibrozil | 2000 |
Global risk assessment for lipid therapy to prevent coronary heart disease.
Topics: Blood Flow Velocity; Carotid Arteries; Coronary Disease; Exercise Test; Gemfibrozil; Homocysteine; H | 2000 |
Conclusions from the VA-HIT study.
Topics: Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Hypolipoproteinemias; | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dise | 2000 |
Therapy and clinical trials.
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2 | 2000 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; | 2001 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Hu | 2000 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
Topics: Acute Kidney Injury; Aged; Bezafibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypo | 2001 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; | 2002 |
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Incidence; Lipids; | 1992 |
[The cholesterol question. Disinformed information].
Topics: Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Coronary Dise | 1991 |
Helsinki gemfibrozil study: another look.
Topics: Coronary Disease; Finland; Gemfibrozil; Humans; Male | 1990 |
Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipoprotein | 1990 |
Treatment of hyperlipidaemias. Current avenues and new horizons.
Topics: Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; H | 1989 |
Lipid-lowering drugs.
Topics: Cataract; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Pentanoic A | 1988 |
Lipid level alterations in the Helsinki Heart Study.
Topics: Cholesterol, HDL; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipoproteinemias; Triglycerid | 1989 |
Gemfibrozil and coronary heart disease.
Topics: Accidents; Adult; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Pe | 1988 |
Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia.
Topics: Adult; Bile Acids and Salts; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Huma | 1988 |
Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease.
Topics: Adult; Combined Modality Therapy; Coronary Disease; Drug Evaluation; Exercise Test; Female; Gemfibro | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet | 1988 |